Skip to content

PLEASURE (Pleasing Lovers, Efficacy, Arousal, Satisfaction, and Uptake Research on Eroxon)

PLEASURE (Pleasing Lovers, Efficacy, Arousal, Satisfaction, and Uptake Research on Eroxon): A Pilot Randomized Trial of Eroxon® Gel as an Adjunct to Tadalafil in Young Men With Diabetes-Associated Erectile Dysfunction

Status
Not yet recruiting
Phases
Phase 4
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT07636161
Enrollment
30
Registered
2026-06-09
Start date
2026-09-01
Completion date
2027-09-01
Last updated
2026-06-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Type 2 Diabetes, Type 2 Diabetes (T2DM)

Brief summary

The purpose of this research study is to look at whether Eroxon® gel when used together with tadalafil, may help improve erectile function in men ages 18 to 40 who have type 2 diabetes.

Interventions

DEVICEEroxon®

Participants will receive a 12-week supply of Eroxon® and will be instructed to apply the gel prior to each sexual encounter as directed at enrollment.

DRUGtadalafil

Tadalafil is administered as standard of care at dose and schedule determined by the treating clinician.

Sponsors

University of Miami
Lead SponsorOTHER
Sexual Medicine Society of North America Inc.
CollaboratorUNKNOWN

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
MALE
Age
18 Years to 40 Years
Healthy volunteers
No

Inclusion criteria

* Male sex at birth * Age 18-40 years * Diagnosis of type 2 diabetes mellitus * Diagnosis of erectile dysfunction * Currently prescribed tadalafil * Have a sexual partner willing to complete a survey * Ability to provide informed consent

Exclusion criteria

* Type 1 diabetes mellitus * Severe psychiatric illness that would impair participation * Use of nitrates or contraindications to sexual activity * Known allergy to Eroxon® gel components * Participation in another interventional sexual health study

Design outcomes

Primary

MeasureTime frameDescription
Change in Erectile FunctioningBaseline to Week 12Erectile function assessed using the International Index of Erectile Function-5 (IIEF-5), a validated 5-item patient-reported questionnaire. Total scores range from 5 to 25, with higher scores indicating better erectile function.

Secondary

MeasureTime frameDescription
Change in Patient AdherenceBaseline to Week 12Patient adherence assessed using the Medication Adherence Report Scale-5 (MARS-5), a validated five-item self-report questionnaire measuring both intentional and unintentional non-adherence. Each item is scored on a 5-point Likert scale, with total scores ranging from 5 to 25, and higher scores indicating better adherence.
Change in Partner AcceptabilityBaseline to Week 12Partner acceptability assessed using the Sexual Life (ISL) scale, a validated 11-item questionnaire evaluating satisfaction and acceptability related to sexual activity. Each item is scored on a 5-point Likert scale, with total scores ranging from 5 to 25, with higher scores indicating greater partner satisfaction and acceptability.

Countries

United States

Contacts

CONTACTAshley Gray
ajg2940@med.miami.edu786-909-3719
PRINCIPAL_INVESTIGATORSonjia Kenya, E.D

University of Miami

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Jun 10, 2026